{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-24-000004","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.471108+00:00","generated_at":"2026-06-07T02:27:09.515966+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%","bullets":["Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.","Q4 instruments revenue ~$38.4M (+72% YoY), driven by Spatial ($27.2M) and Chromium ($11.1M).","Q4 consumables revenue ~$140.3M (+7% YoY); services revenue ~$5.3M (+129% YoY).","Cumulative instruments sold exceeded 5,900 as of year-end 2023, including over 5,150 Chromium, 500 Visium, 250 Xenium.","Final audited results expected in February 2024 earnings call; preliminary figures subject to adjustment."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-24-000004","json":"https://secwatch.observer/filing/0001770787-24-000004.json","markdown":"https://secwatch.observer/filing/0001770787-24-000004.md","text":"https://secwatch.observer/filing/0001770787-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/0001770787-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/txg-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:27:09.515966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"152a596499f6539eb4f4aa759240e64a12c9ce31","claim":"10x Genomics, Inc. reported the three months ended December 31, 2023 results: revenue $184.0 million.","evidence_excerpt":"Revenue of approximately $184.0 million for the three months ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/0001770787-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$184.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"62fd56d5b936bb27c415234040ccfc357a53a80a","claim":"10x Genomics, Inc. reported the year ended December 31, 2023 results: revenue $618.7 million.","evidence_excerpt":"Revenue of approximately $618.7 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078724000004/0001770787-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$618.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}